Astellas Pharma (ALPMY) reports H1 consolidated net sales ( ¥ millions) of ¥556,702, up 16.7% Y/Y.
Net income ( ¥ millions) for H1 falls 16% Y/Y to ¥48.195. (full results)
Backing out FQ1 sales of $82M gets ~$108M in U.S. Xtandi sales for FQ2.
These numbers are likely behind the rally in shares of Medivation (MDVN +10.1%), Astellas' Xtandi partner.